A61P 21 - Drugs for disorders of the muscular or neuromuscular system

Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
10/2011
10/27/2011	US20110263594 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors
10/27/2011	US20110263593 NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS
10/27/2011	US20110263589 Method for preventing or treating a glucocorticoid receptor-related disease
10/27/2011	US20110263577 Novel oxadiazolyl-diazabicyclononane derivatives and their medical use
10/27/2011	US20110263567 Compounds for inhibiting semicarbazide-sensitive amine oxidase (ssao) / vascular adhesion protein-1 (vap-1) and uses thereof for treatment and prevention of diseases
10/27/2011	US20110263553 Steroid analogues for neuroprotection
10/27/2011	US20110263027 Adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
10/27/2011	US20110262552 Compositions Comprising Plant Extracts and Use Thereof for Treating Inflammation
10/27/2011	US20110262542 Controlled Delivery of Tetracycline Compounds and Tetracycline Derivatives
10/27/2011	US20110262422 Orally administrable dosage forms comprising angiogenin and uses thereof
10/27/2011	US20110262419 Specifically targeted catalytic antagonists and uses thereof
10/27/2011	US20110262395 Sensory receptors for chronic fatigue and pain and uses thereof
10/27/2011	CA2833908A1 Cns targeting aav vectors and methods of use thereof
10/27/2011	CA2796637A1 Certain amino-pyrimidines, compositions thereof, and methods for their use
10/26/2011	EP2380907A1 Methods and compositions for the treatment of antibody mediated neuropathies
10/26/2011	EP2380581A1 Muscle-building agent
10/26/2011	EP2379502A2 Novel forms of eperisone
10/26/2011	EP2379499A1 New salts
10/26/2011	EP2379498A1 New polymorphic form of 1- (4- { l- ý (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino¨-ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
10/26/2011	EP2193200B1 Nucleic acid codifying for a utrophin transcription specific regulating protein, protein codified thereby and uses thereof
10/26/2011	EP2026788B1 Therapeutic combination for painful medical conditions
10/26/2011	EP2004176B1 USE OF N- ( DIBENZ (b, f) OXEPIN-10-YLMETHYL ) N-METHYL-N- PROP- 2 -YNYLAMINE (OMIGAPIL) FOR THE PROPHYLAXIS AND / OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHY OR MYOPATHY RESULTING FROM COLLAGEN VI DEFICIENCY
10/26/2011	CN1922313B Acid alpha-glucosidase and fragments thereof
10/26/2011	CN1662243B Pharmaceutical composition
10/26/2011	CN102227225A Compositions and methods for tissue repair with extracellular matrices
10/26/2011	CN102225194A Use of Bv8 and/or EG-VEGF to promote hematopoiesis
10/26/2011	CN101048166B Abnormal protein removing composition
10/25/2011	US8044182 Adiponectin and uses thereof
10/25/2011	US8044070 Heteroaryloxy nitrogenous saturated heterocyclic derivative
10/25/2011	US8044040 e.g. 3-{3-Cyano-6-[(2,2-dimethyl-propyl)-methyl-amino]-5-fluoro-pyridin-2-ylamino}-N-methoxy-4-methyl-benzamide; via p38 kinase inhibition; (anilino)(halo)pyrimidine or (anilino)(amino)pyrimidine derivatives; rheumatoid arthritis, psoriasis, Crohn's Disease, osteoarthritis or osteoporosis
10/25/2011	US8044018 Reagents and methods for smooth muscle therapies
10/20/2011	WO2011130515A1 Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
10/20/2011	WO2011101866A3 Gastric retention formulation containing baclofen
10/20/2011	US20110258713 Compositions and methods for re-programming cells without genetic modification
10/20/2011	US20110258712 Myostatin isoform
10/20/2011	US20110257271 Derivatives of dimethylcurcumin
10/20/2011	US20110257230 Benzimidazole derivatives and their use for modulating the gabaa receptor complex
10/20/2011	US20110257223 Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
10/20/2011	US20110257210 Benzimidazole derivatives and their use for modulating the gabaa receptor complex
10/20/2011	US20110257208 Compounds useful as faah modulators and uses thereof
10/20/2011	US20110257176 Nitrogen heterocycle derivatives as proteasome modulators
10/20/2011	US20110257171 Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors
10/20/2011	US20110257150 New salts
10/20/2011	US20110257145 Method of treating neurological diseases
10/20/2011	US20110256186 biomaterial based on wharton's jelly from the human umbilical cord
10/20/2011	US20110256132 Myostatin binding proteins
10/20/2011	US20110256104 Complexing agents for compositions containing inclusion complexes
10/20/2011	US20110253135 Metal coordination complexes of volatile drugs
10/19/2011	EP2377578A1 Stable aqueous compositions comprising amide-protected bioactive creatine species and uses thereof
10/19/2011	EP2376484A1 Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
10/19/2011	CN102223884A Solid pharmaceutical composition
10/19/2011	CN102219837A Recombinant full-length A-type botulinum toxin mutant vaccine
10/19/2011	CN102218130A Pharmaceutical composition for treating arthralgia syndrome and preparation method thereof
10/19/2011	CN102218117A Fire treatment liquid embrocation for external application and preparation method thereof
10/18/2011	CA2470643C Cleavable reagents for specific delivery to disease sites
10/18/2011	CA2337328C Biocompatible polymers, preparation method and compositions containing same
10/13/2011	WO2011125836A1 Therapeutic agent or prophylactic agent for fibromyalgia
10/13/2011	US20110251286 Crystalline salts and/or co-crystals of O-desmethyltramadol
10/13/2011	US20110251280 Stable Aqueous Compositions Comprising Amide-Protected Bioactive Creatine Species and Uses Thereof
10/13/2011	US20110251207 Biaryl-spiroaminooxazoline analogues as alpha 2c adrenergic receptor modulators
10/13/2011	US20110250200 Soluble lymphotoxin-beta receptor fusion protein and methods for inhibiting lymphotoxin beta-receptor signaling
10/13/2011	US20110250186 Methods for promoting wound healing and muscle regeneration with the cell signaling protein nell1
10/13/2011	CA2793709A1 Therapeutic agent or prophylactic agent for fibromyalgia
10/12/2011	EP2374885A2 ENA nucleic acid drugs modifying splicing in mRNA precursor
10/11/2011	US8034958 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
10/11/2011	US8034955 triterpenoids such as 2-cyano-3,12-dioxoolean-1,9-dien-28oic acid, used for inhibiting gamma -inteferon-induced nitric oxide production in macrophages; preventing cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis
10/11/2011	US8034615 Method for treating autoimmune diseases and screening method for preventive or therapeutic agent for the same
10/11/2011	CA2488934C Aryl oxime derivatives as phosphodiesterase iv inhibitors for the treatment of diseases
10/11/2011	CA2472479C Deazapurines and uses thereof
10/11/2011	CA2457054C Activator of peroxisome proliferator-activated receptor .delta.
10/11/2011	CA2394862C Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder
10/06/2011	WO2011123456A1 Botulinum toxin dosage regimen for chronic migraine prophylaxis
10/06/2011	WO2011121109A1 Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
10/06/2011	US20110247087 Regulation of endogenous gene expression in cells using zinc finger proteins
10/06/2011	US20110245323 RIG-Like Helicase Innate Immunity Inhibits VEGF-Induced Tissue Responses
10/06/2011	US20110245312 Amino acid based compositions for the treatment of pathological conditions distinguished by insufficient mitochondrial function
10/06/2011	US20110245222 Methods for Using Carboxamide, Sulfonamide and Amine Compounds
10/06/2011	US20110243953 Neutralizing antibodies against gdf-8 and uses therefor
10/06/2011	US20110243881 Biocompatible polymers, process for their preparation and compositions containing them
10/06/2011	CA2794782A1 Botulinum toxin dosage regimen for chronic migraine prophylaxis
10/05/2011	EP2371861A1 Monoclonal antibodies against extracellular loops of C5aR
10/05/2011	EP2371393A1 Preventive or remedy for inflammatory disease
10/05/2011	EP1463497B1 Treating muscle wasting with selective androgen receptor modulators
10/05/2011	CN1446227B Novel fibroblast growth factor (FRF23) and method for use
10/05/2011	CN101380464B Method for treating a movement disorder
10/05/2011	CN101224201B Application of dual inhibitor for dopamine and norepinephrine transfer protein
10/04/2011	US8030517 CCR9 inhibitors and methods of use thereof
10/04/2011	US8030296 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase
10/04/2011	US8030275 Methods for treating obesity using fibroblast growth factor-like polypeptides
10/04/2011	CA2673462C Solid oral dosage forms of valsartan
10/04/2011	CA2491079C Therapeutic piperazine derivatives useful for treating pain
10/04/2011	CA2434773C Piperazinylcarbonylquinolines and -isoquinolines
09/2011
09/29/2011	WO2011117448A1 Compounds for use in the treatment of diseases based on the expression of toxic transcripts
09/29/2011	WO2011047093A3 Stem cells for musculoskeletal tissue repair
09/29/2011	US20110239312 Methods of diagnosing and treating motor neuron diseases
09/29/2011	US20110237666 Hydroxybutyrate ester and medical use thereof
09/29/2011	US20110237664 Selective androgen receptor modulators for treating diabetes
09/29/2011	US20110237659 Chromenone derivatives as trpv3 antagonists
09/29/2011	US20110237648 Rna interference in skin indications
09/29/2011	US20110237617 Thieno[2,3-c] isoquinolines for use as inhibitors of parp

1 ... 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 ... 233